Halberd Corp Stock Price, News & Analysis

Halberd Corporation (OTC PINK: HALB) has obtained exclusive rights to a provisional patent for a nasal spray aimed at preventing COVID-19 transmission. This development is based on research indicating that children have fewer ACE2 receptors, which the virus uses to infect cells. Halberd, in collaboration with Arizona State University, is pursuing a comprehensive approach involving a preventative nasal spray, fast diagnostics, and therapeutic treatments. The company is ready to initiate testing in South America and is seeking partners for pharmaceutical development.

Halberd Corporation (OTC PINK: HALB) has announced a collaborative research project with Arizona State University to develop a rapid diagnostic test for Covid-19. The focus is on the coronavirus spike antigen, which is critical to the virus's contagiousness. Feasibility samples of an antibody conjugate are expected in four weeks, potentially enabling a quick testing method using saliva or blood. The company holds exclusive rights to relevant provisional patents for Covid-19 treatments.

Halberd Corporation (OTC PINK: HALB) announced a significant breakthrough in its COVID-19 research project with Arizona State University. Dr. Qiang Chen's team successfully recreated the coronavirus spike protein disease antigen, paving the way for the identification of proprietary antibodies expected within two weeks. The joint efforts aim to secure patent protections for their findings. The company's patented extracorporeal process could improve detection and treatment of COVID-19 while minimizing side effects associated with traditional drug therapies.

Halberd Corporation (OTC PINK: HALB) has outlined the second stage goals of its $1.4 million partnership with Arizona State University. This stage focuses on utilizing a dialysis method to identify Covid-19 samples through the removal of fluorescent antibody-antigen complexes. Initial findings from the first phase are promising, with results expected soon. Halberd's technology aims to enhance diagnosis and treatment of Covid-19, with multiple methods under investigation for optimal effectiveness. The company remains debt-free and compliant with OTC reporting requirements.

Halberd Corporation (HALB) announced a $1.4 million research partnership with Arizona State University aimed at developing a rapid Covid-19 test. This will involve creating a fluorescent antibody to identify Covid-19 in various samples. The project includes two provisional patents: one for treating Covid-19 and another for rapid identification. Initial results are expected within a month. CEO William A. Hartman emphasized the urgency for rapid identification due to market needs. The company remains debt-free and fully compliant with reporting requirements.

Halberd Corporation announced the commencement of research at Arizona State University (ASU) aimed at developing antibodies related to COVID-19. This research supports two issued patents and three provisional patent applications focusing on the extracorporeal removal of the virus' antigens from blood. The CEO expressed confidence in ASU's capabilities, particularly in the initial research phase. Halberd holds exclusive rights to various COVID-19 treatment patents, enhancing its position in the healthcare space amid the pandemic.

Halberd Corporation (OTC PINK: HALB) has partnered with Arizona State University (ASU) for research focused on developing a Covid-19 treatment. ASU is a leading institution in health-related funding and innovation. CEO William A. Hartman emphasized ASU's strong research capabilities, which were evaluated against six other universities before the partnership. The project aims not only to tackle Covid-19 but also to address other blood-borne and neurologic diseases through their patented extracorporeal treatment process.

Halberd Corporation (OTC PINK: HALB) announced a partnership with Arizona State University (ASU) on August 31, 2020, to develop treatments for Covid-19. This project will support Halberd's existing patents and provisional applications for extracorporeal removal of the virus' antigens from blood. The focus is also on developing neutralizing antibodies and potential therapeutic medications. Halberd possesses exclusive rights to multiple Covid-19-related patents.

Halberd Corp. (OTC PINK: HALB) announced the successful completion of a partnership with a major research university to develop compounds for its patented extracorporeal treatment for Covid-19. The contract terms are finalized, and signatures are in process, with more details to be released soon. Halberd holds exclusive rights to multiple provisional patents related to Covid-19 treatments. The company is debt-free and compliant with OTC Market reporting requirements.